TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23700731

Group type: EXPERIMENTAL
Intervention: Low-dose daily de-escalatory administration of tadalafil for 2 months
Number of subjects: 84

Group type: COMPARATOR
Intervention: On-demand medication of tadalafil for 2 months
Number of subjects: 84
Study: 20416893

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg orally, 3 times daily for 7 days preoperatively
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group receiving oral placebo
Number of subjects: 85
Study: 19095497

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 17100936

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 15304144

Group type: EXPERIMENTAL
Intervention: Training in shared decision making (SDM) or combined with risk communication (RC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risk communication (RC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training in SDM or combined with RC
Number of subjects: 0
Study: 11776507

Group type: EXPERIMENTAL
Intervention: 25 microg estradiol vaginal tablet
Number of subjects: 53

Group type: COMPARATOR
Intervention: 1 g conjugated estrogen cream
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 53
Study: 9603794

Group type: EXPERIMENTAL
Intervention: Goggles reducing visible-light exposure by 97% and ultraviolet-light exposure by 100%
Number of subjects: 409

Group type: COMPARATOR
Intervention: Typical nursery lighting (control group)
Number of subjects: 409
Study: 8090608

Group type: EXPERIMENTAL
Intervention: Beta 2-agonist (terbutaline, 500 micrograms via nebuhaler)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beta 2-agonist (terbutaline)
Number of subjects: 10
Study: 2899772

Group type: EXPERIMENTAL
Intervention: 1‐hour intravenous infusion of 1.5 MU of streptokinase
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: 160 mg/day enteric‐coated aspirin for one month
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Combination of streptokinase and aspirin
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Streptokinase alone
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Streptokinase and aspirin
Number of subjects: 17187
Study: 30746695

Group type: EXPERIMENTAL
Intervention: Cross-sectional approaches using HIV diagnostic tests and biomarkers of recent infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random effects model to account for heterogeneity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Permutation test for null hypothesis of no heterogeneity
Number of subjects: 0
Study: 28112800

Group type: EXPERIMENTAL
Intervention: iPad version of the Dermatology Life Quality Index (DLQI)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Paper version of the Dermatology Life Quality Index (DLQI)
Number of subjects: 104
Study: 25900704

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced spectral mammography (CESM)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Contrast-enhanced MRI (CEMRI)
Number of subjects: 49
Study: 23358966

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Individualized dosing of EC‐Asnase (ID)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 492

Group type: COMPARATOR
Intervention: Fixed dosing of EC‐Asnase (FD)
Number of subjects: 492
Study: 22155904

Group type: EXPERIMENTAL
Intervention: Valganciclovir (900 mg once daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Valacyclovir (2 g four times daily)
Number of subjects: 36
Study: 19301011

Group type: EXPERIMENTAL
Intervention: Primary electronically cleansed 3D
Number of subjects: 72

Group type: COMPARATOR
Intervention: Primary uncleansed 2D
Number of subjects: 72
Study: 16845914

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 102

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 102
Study: 15295326

Group type: EXPERIMENTAL
Intervention: stainless steel dowels (ParaPost)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: glass fiber dowels (Snowpost)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: resin‐supported polyethylene fiber (Ribbond) dowels
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: zirconia dowels (Cosmopost)
Number of subjects: 41
Study: 14676767

Group type: EXPERIMENTAL
Intervention: Tetracycline mixed with calcium hydroxide (CH)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Erythromycin mixed with calcium hydroxide (CH)
Number of subjects: 55
Study: 10994883

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) for 5 consecutive hours per day plus physical therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Physical therapy only
Number of subjects: 51
Study: 8793703

Group type: EXPERIMENTAL
Intervention: Calcium antagonists or angiotensin converting enzyme inhibitors (n = 266)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo administration (n = 116)
Number of subjects: 382
Study: 1465059

Group type: EXPERIMENTAL
Intervention: Normal protein diet (1.1 +/- 0.3 g/kg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.7 +/- 0.1 g/kg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dietary manipulation (low-protein and normal protein diets)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vegetarian soy diet (0.71 +/- 0.36 g/kg ideal body weight/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Free diet (baseline control period)
Number of subjects: 44
Study: 3871797

Group type: EXPERIMENTAL
Intervention: Enteric-coated erythromycin pellets (250 mg base)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate (400 mg base equivalent)
Number of subjects: 24
Study: 3622938

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg p.o.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31232853

Group type: EXPERIMENTAL
Intervention: Dynamic needle tip positioning (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Static group (n = 30)
Number of subjects: 60
Study: 28719580

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25978046

Group type: EXPERIMENTAL
Intervention: Melissa officinalis extract containing 500 mg rosmarinic acid (fasted state)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Melissa officinalis extract containing 500 mg rosmarinic acid (fed state)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Melissa officinalis extract containing 500 mg rosmarinic acid
Number of subjects: 11
Study: 23911602

Group type: EXPERIMENTAL
Intervention: Omission of secondary casts obtained from impressions in border moulded custom trays (Group 1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Omission of secondary casts and face-bow articulator mounting (Group 2)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Omission of face-bow mounting (Group 3)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No steps omitted (control, Group 4)
Number of subjects: 43
Study: 21739499

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone pessaries from 20-24 weeks until 34 weeks' gestation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo pessaries from 20-24 weeks until 34 weeks' gestation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone pessaries
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo pessaries
Number of subjects: 72
Study: 19114860

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) with protease inhibitor dose escalation
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 183
Study: 16764552

Group type: EXPERIMENTAL
Intervention: Timed Up and Go Test (TUG) completion
Number of subjects: 2463

Group type: COMPARATOR
Intervention: Other significant predictors
Number of subjects: 2463
Study: 15663123

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (25 g carbohydrates)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 11510870

Group type: EXPERIMENTAL
Intervention: Discontinuous training protocol (25 times 80 s at 35% VO2max and 40 s at 80% VO2max)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Continuous training protocol (50 min at 50% VO2max)
Number of subjects: 14
Study: 9150807

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) monotherapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) add-on treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study: 7919566

Group type: EXPERIMENTAL
Intervention: Tacrine (cholinesterase inhibitor)
Number of subjects: 0
Study: 3585450

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulfate (MSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS)
Number of subjects: 0
Study: 31843338

Group type: EXPERIMENTAL
Intervention: Chemotherapy (182 patients)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Radiotherapy (178 patients)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Standard radiotherapy (108 patients)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Reduced high‐dose volume radiotherapy (111 patients)
Number of subjects: 458
Study: 30989173

Group type: EXPERIMENTAL
Intervention: Augmentor software package for image augmentation
Number of subjects: 0
Study: 27900942

Group type: EXPERIMENTAL
Intervention: GFR < 45 mL/min/1.73 m2
Number of subjects: 2338

Group type: COMPARATOR
Intervention: GFR ≥ 90 mL/min/1.73 m2
Number of subjects: 2338
Study: 26322635

Group type: EXPERIMENTAL
Intervention: 30‐mL balloon for a maximum of 12 hours
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 30‐mL balloon for a maximum of 24 hours
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 80‐mL balloon for a maximum of 12 hours
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 80‐mL balloon for a maximum of 24 hours
Number of subjects: 504

Group type: COMPARATOR
Intervention: 12-hour Foley catheter groups
Number of subjects: 504

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 504

Group type: COMPARATOR
Intervention: Higher balloon volume (80‐mL) and longer ripening time (24 hours)
Number of subjects: 504
Study: 23237821

Group type: EXPERIMENTAL
Intervention: Enhanced home visiting program
Number of subjects: 8080

Group type: COMPARATOR
Intervention: Standard home visiting program
Number of subjects: 8080
Study: 22016915

Group type: EXPERIMENTAL
Intervention: Adper Easy Bond (AEB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AEB + Hydrophobic Resin (HR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etch + AEB
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etch + AEB + HR
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adper Single Bond Plus (ASB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adper Scotchbond Multi-Purpose (SBMP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AEB
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AEB + HR
Number of subjects: 30

Group type: COMPARATOR
Intervention: ASB
Number of subjects: 30

Group type: COMPARATOR
Intervention: SBMP
Number of subjects: 30
Study: 18556090

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saccharin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium chloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quinine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Starch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium glutamate
Number of subjects: 0
Study: 16879332

Group type: EXPERIMENTAL
Intervention: Wand (computerized device)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conventional buccal infiltration (CBi)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Periodontal ligament injection (PDLi)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Palatal approach-anterior superior alveolar (P-ASA) nerve block
Number of subjects: 138
Study: 12586320

Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol with diclofenac sodium (NSAID)
Number of subjects: 0
Study: 11421896

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium, two puffs twice daily, 0.002 g/puff
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo, two puffs twice daily
Number of subjects: 39
Study: 9508754

Group type: EXPERIMENTAL
Intervention: Diacarb administered after the proposed protocols
Number of subjects: 130
Study: 8514653

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of netilmicin (6 mg/kg body weight)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Thrice-daily dosing of netilmicin (6 mg/kg body weight)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of netilmicin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Thrice-daily dosing of netilmicin
Number of subjects: 116
Study: 3734289

Group type: EXPERIMENTAL
Intervention: Single dose of 2.2 or 4.4 mg of azelastine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multiple dose therapy with 4.4 mg of azelastine for 21 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 20
Study: 30531384

Group type: EXPERIMENTAL
Intervention: L‐dopa ON
Number of subjects: 27

Group type: COMPARATOR
Intervention: L‐dopa OFF
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Practice dose and acquisition rate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Plateau during practice
Number of subjects: 27
Study: 28205481

Group type: EXPERIMENTAL
Intervention: 6‐0 Prolene
Number of subjects: 16

Group type: COMPARATOR
Intervention: 6‐0 Nylon
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both sutures (Prolene and Nylon)
Number of subjects: 16
Study: 25917017

Group type: EXPERIMENTAL
Intervention: Electrical stimulation therapy on the suprahyoid muscles (SM group, n = 66)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Electrical stimulation therapy with electrodes on both suprahyoid and infrahyoid muscles (SI group, n = 66)
Number of subjects: 132
Study: 23816490

Group type: EXPERIMENTAL
Intervention: Obesity prevention intervention
Number of subjects: 421

Group type: COMPARATOR
Intervention: Contact Control condition
Number of subjects: 421
Study: 20030775

Group type: EXPERIMENTAL
Intervention: High-intensity strength training (S)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined training (SE)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Endurance training (E)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 96
Study: 19751115

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (10/160 mg o.d.)
Number of subjects: 944

Group type: COMPARATOR
Intervention: Amlodipine (10 mg o.d.)
Number of subjects: 944
Study: 16954960

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg for 14 days)
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1110
Study: 15274104

Group type: EXPERIMENTAL
Intervention: A/C + VG
Number of subjects: 18

Group type: COMPARATOR
Intervention: A/C
Number of subjects: 18
Study: 11813617

Group type: EXPERIMENTAL
Intervention: Octreotide 300 micrograms t.i.d. for seven days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Octreotide 200 micrograms t.i.d. for seven days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms t.i.d. for seven days
Number of subjects: 120
Study: 9284731

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.036 U/kg.day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8329164

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Interplak)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional manual toothbrush (Butler 311)
Number of subjects: 20
Study: 3819198

Group type: EXPERIMENTAL
Intervention: Percutaneous insertion
Number of subjects: 101

Group type: COMPARATOR
Intervention: Surgical insertion
Number of subjects: 101
Study: 29537647

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.625 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.625 mg/day) + medroxyprogesterone acetate (MPA, 2.5 mg/day)
Number of subjects: 8
Study: 26640129

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 12
Study: 25365268

Group type: EXPERIMENTAL
Intervention: Non-invasive assessment by a screening radiologist
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual care (multidisciplinary hospital assessment)
Number of subjects: 366
Study: 22626586

Group type: EXPERIMENTAL
Intervention: Intervention group (12 hour maximum shift schedule compliant with 2011 restrictions)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (every fourth night, 30-hour call schedule)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study: 20393978

Group type: EXPERIMENTAL
Intervention: Exemestane alone or following tamoxifen
Number of subjects: 9779

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery with radiotherapy
Number of subjects: 9779

Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection
Number of subjects: 9779
Study: 19063808

Group type: EXPERIMENTAL
Intervention: Web-based telediabetes programs
Number of subjects: 0
Study: 16085942

Group type: EXPERIMENTAL
Intervention: Indocyanine green‐assisted internal limiting membrane peeling
Number of subjects: 49

Group type: COMPARATOR
Intervention: No internal limiting membrane peeling
Number of subjects: 49
Study: 12369293

Group type: EXPERIMENTAL
Intervention: Misgav‐Ladach method
Number of subjects: 110

Group type: COMPARATOR
Intervention: Pfannenstiel method
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 110
Study: 11360606

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 0.75 mg taken twice with 12 hours apart
Number of subjects: 1276

Group type: COMPARATOR
Intervention: Mifepristone (Mife-) single dose of 10 mg and placebo 12 hours after
Number of subjects: 1276
Study: 7484025

Group type: EXPERIMENTAL
Intervention: Combination of 0.5 times the ED50 doses of mivacurium and pancuronium (cMP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: cMP administered to the same IV-line
Number of subjects: 70

Group type: COMPARATOR
Intervention: cMP administered to two separate IV-lines in opposite hands
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: cMP
Number of subjects: 70
Study: 1322075

Group type: EXPERIMENTAL
Intervention: Vancomycin (125 mg four times daily for 10 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg twice daily for 10 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (three times daily for 10 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 30
Study: 6095356

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Racemic sodium lactate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine (after treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpsychiatric control subjects
Number of subjects: 0
Study: 31663443

Group type: EXPERIMENTAL
Intervention: ADC gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29063592

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (Ω3)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (Ω3) alone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (Ω3) combined with psychoeducational psychotherapy (PEP)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Psychoeducational psychotherapy (PEP) monotherapy
Number of subjects: 95
Study: 24578470

Group type: EXPERIMENTAL
Intervention: icodextrin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (glucose-based dialysis solution)
Number of subjects: 53
Study: 22339101

Group type: EXPERIMENTAL
Intervention: Hegu acupuncture
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Standard acupuncture
Number of subjects: 187

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 187
Study: 19446314

Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 274

Group type: COMPARATOR
Intervention: Treosulfan
Number of subjects: 274
Study: 17885238

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (retreatment)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (retreatment) for small aneurysms (< or =10 mm) with small necks (< or =4 mm)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Risk group (n = 128)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Patients with residual aneurysm after the first treatment
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Retreatment procedures
Number of subjects: 323
Study: 15070873

Group type: EXPERIMENTAL
Intervention: GnRH agonist (0.1 mg triptorelin)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 11576319

Group type: EXPERIMENTAL
Intervention: Anti-hypertensive treatment for 3 months with a calcium-antagonist in randomized combination with either an ACE inhibitor or a beta-blocker
Number of subjects: 29

Group type: COMPARATOR
Intervention: Baseline hypertensives
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 29
Study: 9592630

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 96

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 96

Group type: COMPARATOR
Intervention: Other antidepressants or lithium
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 96